Structure-activity relationship of 1-desamino-8-D-arginine vasopressin as an antiproliferative agent on human vasopressin V2 receptor-expressing cancer cells

Molecular Medicine Reports

Volumn 9, Issue 6, 2014, Pages 2568-2572

  Pastrian, María B ^a   Guzmán, Fanny ^b   Garona, Juan ^c   Pifano, Marina ^c   Ripoll, Giselle V ^c   Cascone, Osvaldo ^a   Ciccia, Raciela N ^d   Albericio, Fernando ^e,f,g   Gómez, Daniel E ^c   Alonso, Daniel F ^c   Iannucci, Nancy B ^a,d  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE VALPARAÍSO   (Chile)

^c UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^d Therapeutic Peptides Research   (Argentina)

^e INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^f UNIVERSITY OF BARCELONA   (Spain)

^g UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Ala scanning; Breast cancer; Cytostatic effect; Desmopressin; V2 receptor; Vasopressin analogs

Indexed keywords

ALANINE; AMINO ACID; CELL SURFACE RECEPTOR; DESMOPRESSIN; HYDROXYPROLINE; PROLINE; VASOPRESSIN V2 RECEPTOR; ARGIPRESSIN[1 DEAMINO]; VASOPRESSIN RECEPTOR;

AMINO TERMINAL SEQUENCE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER THERAPY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH; AGONISTS; AMINO ACID SEQUENCE; ANALOGS AND DERIVATIVES; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; TUMOR CELL LINE;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; DEAMINO ARGININE VASOPRESSIN; HUMANS; RECEPTORS, VASOPRESSIN; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR STEM CELL ASSAY;

EID: 84899696883     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2140     Document Type: Article

References (22)

1. Manning M, Stoev S, Chini B, Durroux T, Mouillac B and Guillon G: Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 ant OT receptors: research tools and potential therapeutic agents. Prog Brain Res 170: 473-512, 2008. (Pubitemid 352014896)
2. Manning M, Misicka A, Olma A, Bankowski K, Stoev S, Chini B, Durroux T, Mouillac B, Corbani M and Guillon G: Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol 24: 609-628, 2012.
3. North WG, Fay MJ and Du J: MCF-7 breast cancer cells express normal forms of all vasopressin receptors plus an abnormal V2R. Peptides 20: 837-842, 1999. (Pubitemid 29378285)
4. Ripoll GV, Giron S, Krzymuski MJ, Hermo GA, Gomez DE and Alonso DF: Antitumor effects of desmopressin in combination with chemotherapeutic agents in a mouse model of breast cancer. Anticancer Res 28: 2607-2611, 2008.
5. Alonso DF, Ripoll GV, Garona J, Iannucci NB and Gomez DE: Metastasis: recent discoveries and novel perioperative treatment strategies with particular interest in the hemostatic compound desmopressin. Curr Pharm Biotech 12: 1974-1980, 2011.
6. Cunningham BC and Wells JA: High-resolution epitope mapping of hGH receptor interactions by alanine-scanning mutagenesis. Science 244: 1081-1085, 1989. (Pubitemid 19152300)
7. Beck-Sickinger AG, Wieland HA, Wittneben H, Willim KD, Rudolf K and Jung G: Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations. Eur J Biochem 225: 947-958, 1994. (Pubitemid 24342539)
8. Nicole P, Lins L, Rouyer-Fessard C, Drouot C, Fulcrand P, Thomas A, Couvineau A, Martínez J, Brasseur R and Laburthe M: Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J Biol Chem 275: 24003-24012, 2000. (Pubitemid 30624691)
9. Quartara L, Ricci R, Meini S, et al: Ala scan analogues of HOE 140. Synthesis and biological activities. Eur J Med Chem 35: 1001-1010, 2000.
10. Nam J, Shin D, Rew Y and Boger DL: Alanine scan of [L-Dap(2)] ramoplanin A2 aglycon: assessment of the importance of each residue. J Am Chem Soc 129: 8747-8755, 2007. (Pubitemid 47492062)
11. Houghten RA: General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci USA 82: 5131-5135, 1985.
12. Albericio F, Annis I, Royo M and Barany G: Preparation and handling of peptides containing methionine and cysteine. In: Fmoc Solid Phase Peptide Synthesis. A Practical Approach. Chan WC and White PD (eds). Oxford University Press Inc., New York, NY, pp77-114, 2000.
13. Czaplewski C, Kázmierkiewicz R and Ciarkowski J: Molecular modeling of the human vasopressin V2 receptor/agonist complex. J Comp Aided Mol Des 12: 275-287, 1998. (Pubitemid 128510956)
14. Iannucci NB, Ripoll GV, Garona J, Cascone O, Ciccia GN, Gomez DE and Alonso DF: Antiproliferative effect of 1-deamino-8-D-arginine vasopressin analogs on human breast cancer cells. Future Med Chem 3: 1987-1993, 2011.
15. Kowalczyk W, Prahl A, Derdowska I, Sobolewski D, Olejnik J, Zabrocki J, Borovicková L, Slaninová J and Lammek B: Analogues of neurohypophyseal hormones, oxytocin and arginine vasopressin, conformationally restricted in the N-terminal part of the molecule. J Med Chem 49: 2016-2021, 2006.
16. North WG, Pai S, Friedmann A, Yu X, Fay M and Memoli V: Vasopressin gene related products are markers of human breast cancer. Breast Cancer Res Treat 34: 229-235, 1995.
17. Monstein HJ, Truedsson M, Ryberg A and Ohlsson B: Vasopressin receptor mRNA expression in the human gastrointestinal tract. Eur Surg Res 40: 34-40, 2008. (Pubitemid 350085269)
18. North WG, Fay MJ, Longo KA and Du J. Expression of all known vasopressin receptor subtypes by small cell tumors implies a multifaceted role for this neuropeptide. Cancer Res 58: 1866-1871, 1998. (Pubitemid 28217460)
19. Terraube V, Pendu R, Baruch D, Gebbink MF, Meyer D, Lenting PJ and Denis CV. Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost 4: 519-526, 2006.
20. Mochizuki S, Soejima K, Shimoda M, Abe H, Sasaki A, Okano HJ, Okano H and Okada Y: Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor. J Natl Cancer Inst 104: 906-922, 2012.
21. Colgrave ML and Craik DJ: Thermal, chemical and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knot. Biochemistry 43: 5965-5975, 2004. (Pubitemid 38669464)
22. Craik DJ, Cemazar M and Daly NL: The cyclotides and related macrocyclic peptides as scaffolds in drug design. Curr Opin Drug Discovery Devel 9: 251-260, 2006. (Pubitemid 35012711)